New Peptide Research Published This Quarter (Q2 2026)

Q2 2026 (April through June) was a busy quarter for peptide research. Four fields drove most of the publication volume: incretin agonists, regenerative and tissue-repair peptides, mitochondrial peptides, and growth axis peptides. The headline movers were Retatrutide TRIUMPH Phase III readouts, a Tirzepatide MASH (metabolic-associated steatohepatitis) Phase III trial, fresh mechanistic work on BPC-157 and TB-500, a Cell Metabolism paper on incretin neural circuits, and a SS-31 Phase II readout in primary mitochondrial disease. This roundup walks through what got published in Q2 2026, structured by therapeutic area. The goal is a quick orientation for laboratory personnel and academic researchers who follow the field, not an exhaustive systematic review. All findings described are from in vitro work, cell culture systems, rodent models, or defined human research trial populations. Nothing here should be read as clinical advice for human use. Compounds in the originlabsresearch.com catalog are supplied as research material for institutional research-use-only work.

Incretin agonists: TRIUMPH and SURMOUNT keep reading out

Q2 2026 publications across the incretin agonist field:

• TK0 TRIUMPH Phase III reported additional individual trial arm results during the quarter, with publications in major endocrinology journals describing measured changes in body weight and metabolic biomarker panels in obesity research populations.
• Tirzepatide MASH Phase III had one readout during the quarter reporting changes in liver histology endpoints alongside the metabolic panel.
• Semaglutide publications added extended cardiovascular outcomes data and additional analyses of SUSTAIN and STEP trial datasets. Reviewers emphasised the continued growth of the long-term outcomes evidence base for the GLP-1 mono-agonist class.
• Cell Metabolism mechanism paper investigated the cellular and molecular basis for differential weight loss efficacy across incretin compounds, with attention to neuronal circuits in the hypothalamic appetite control system.
• Molecular Metabolism biased agonism paper reported signalling profiles at the GLP-1 receptor for several next-generation research peptides, discussing how biased signalling may relate to the gastrointestinal adverse event profile seen in published clinical trials.

Bottom line: the incretin agonist literature continues compounding. Phase III data keeps arriving, and the mechanism side is catching up with detailed receptor pharmacology.

Regenerative and tissue-repair peptides

Q2 2026 publications in this category:

• TK0 added mechanistic cell culture work on the FAK-paxillin pathway (the cell migration signalling axis) and a rodent tendon transection model paper investigating dose-response across a defined concentration range.
• TB-500 (Thymosin Beta-4 fragment 17 to 23) had new in vitro work on G-actin sequestration and the contribution of the central actin-binding motif to the migration and proliferation effects reported in earlier work.
• Thymosin family review appeared during the quarter summarising the preclinical literature on Thymosin Alpha-1 in immune modulation models and on Thymosin Beta-4 in cardiac repair models.
• TK0 (the copper-binding tripeptide) continued to draw attention in dermatology and wound healing research. A Q2 2026 paper reported transcriptomic changes in a cutaneous wound model treated with the peptide.
• Epitalon and related pineal tetrapeptides had additional work in rodent ageing models with telomere length and reproductive endpoint readouts.

Reviewers continue to flag the absence of large controlled human trials as the major gap across this entire field.

Mitochondrial and longevity peptides

Q2 2026 publications:

• TK0 had a new Aging Cell paper investigating metabolic and exercise endpoint readouts in aged rodent models, with the AMPK signalling axis again identified as the central mechanistic candidate. A separate paper explored MOTS-c in a MASLD (metabolic-associated steatotic liver disease) model, reporting changes in hepatic lipid metabolism markers versus controls.
• TK0 (also called Elamipretide) had a Phase II readout in a primary mitochondrial disease research population.
• Humanin family had mechanistic work on the IGF-binding protein interaction and on cytoprotective effects observed in cell culture stress models.
• Next-generation mitochondrial-targeted peptides at earlier development stages appeared in the literature, with design discussion around targeting mitochondrial cardiolipin and other inner-membrane components.

The mitochondrial peptide field remains a research-active area with substantial preclinical evidence and a small but growing body of early clinical research data.

Growth hormone secretagogues and growth axis peptides

Q2 2026 activity in this category:

• Ipamorelin and CJC-1295 had a pharmacokinetic publication characterising plasma growth hormone profiles following combined administration in rodent models, with comparison to single-agent administration.
• Tesamorelin continued to add long-term follow-up data, primarily on visceral adipose tissue endpoints in defined clinical research populations.
• Sermorelin and related GHRH analogues received less attention this quarter, but a broader growth-hormone-releasing peptide literature review was published.
• Hexarelin and GHRP-2 added continued mechanistic work on the ghrelin receptor and on the cardiac receptor system targeted by some secretagogue class members.
• MK-677 (a small-molecule, not a peptide) was discussed in several Q2 2026 review articles comparing peptide and non-peptide growth hormone secretagogues in research settings.

The growth axis field is characterised by extensive preclinical and pharmacokinetic literature with a smaller number of published clinical research reports.

Other notable Q2 2026 publications and recurring open questions

Worth flagging:

• PT-141 (Bremelanotide) had continued attention in central nervous system research, with publications exploring melanocortin receptor signalling in animal models.
• DSIP (delta sleep-inducing peptide) had a small number of publications in animal model sleep architecture research.
• Selank and Semax (Russian-origin nootropic research peptides) continued to draw attention in preclinical anxiety and cognition models. A Q2 2026 paper reported transcriptomic readouts in rodent hippocampal tissue.

Across the broader peptide research field, the same open questions kept recurring in quarterly review articles:

• Receptor identification for peptides with established preclinical activity but no defined high-affinity receptor.
• Long-term safety characterisation in animal model chronic-administration studies.
• Interspecies translation from rodent to higher mammal to human research populations.
• Standardisation of dose-response reporting across published studies.

Q2 2026 added data to several of these questions while leaving others open. BPC-157, Retatrutide, MOTS-c, GHK-Cu, and SS-31 are all supplied at originlabsresearch.com for institutional research-use-only work.

References

1. [1] Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine.
2. [2] Lean MEJ, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rossner S, Torekov S, et al. (2014). Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. International Journal of Obesity. PMID 23736369
3. [3] Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. PMID 25738459
4. [4] Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. PMID 30381366
5. [5] Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, et al. (2013). Toxicity by NSAIDs: counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. PMID 22950504

Frequently asked questions